Business Description
![BridgeBio Pharma Inc BridgeBio Pharma Inc logo](https://static.gurufocus.com/logos/0C0000BMWM.png?14)
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US10806X1028
Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | -1.24 | |||||
Debt-to-Equity | -1.65 | |||||
Debt-to-EBITDA | -3.8 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.4 | |||||
Beneish M-Score | 5.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.6 | |||||
3-Year EBITDA Growth Rate | 4.3 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | 2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.45 | |||||
9-Day RSI | 44.14 | |||||
14-Day RSI | 43.64 | |||||
6-1 Month Momentum % | -33.46 | |||||
12-1 Month Momentum % | 54.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.54 | |||||
Quick Ratio | 5.54 | |||||
Cash Ratio | 3.67 | |||||
Days Payable | 848.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | -13.19 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.91 | |||||
Operating Margin % | -216.34 | |||||
Net Margin % | -246.24 | |||||
FCF Margin % | -277.09 | |||||
ROA % | -84.63 | |||||
ROIC % | -338.33 | |||||
ROC (Joel Greenblatt) % | -2138.82 | |||||
ROCE % | -89.47 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 20.73 | |||||
EV-to-EBIT | -12.91 | |||||
EV-to-Forward-EBIT | -10.7 | |||||
EV-to-EBITDA | -13.09 | |||||
EV-to-Forward-EBITDA | -10.85 | |||||
EV-to-Revenue | 27.28 | |||||
EV-to-Forward-Revenue | 25.84 | |||||
EV-to-FCF | -9.85 | |||||
Earnings Yield (Greenblatt) % | -7.75 | |||||
FCF Yield % | -12.74 |